SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 230 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,263,634 | -8.3% | 82,105 | 0.0% | 0.77% | +11.4% |
| Q2 2023 | $2,468,076 | -17.0% | 82,105 | 0.0% | 0.69% | -14.7% |
| Q1 2023 | $2,974,664 | -9.5% | 82,105 | -10.9% | 0.81% | -4.3% |
| Q4 2022 | $3,285,385 | -20.5% | 92,105 | -24.6% | 0.85% | -25.4% |
| Q3 2022 | $4,133,000 | -29.3% | 122,105 | -39.6% | 1.14% | -17.4% |
| Q2 2022 | $5,844,000 | -18.6% | 202,105 | -9.0% | 1.38% | -6.3% |
| Q1 2022 | $7,178,000 | -38.8% | 222,105 | -44.8% | 1.47% | -37.4% |
| Q4 2021 | $11,725,000 | +9.3% | 402,105 | 0.0% | 2.34% | +2.9% |
| Q3 2021 | $10,724,000 | -13.4% | 402,105 | 0.0% | 2.28% | -3.6% |
| Q2 2021 | $12,380,000 | +17.6% | 402,105 | 0.0% | 2.36% | +19.9% |
| Q1 2021 | $10,527,000 | +4.1% | 402,105 | 0.0% | 1.97% | +1.1% |
| Q4 2020 | $10,116,000 | +37.9% | 402,105 | +14.2% | 1.95% | +28.4% |
| Q3 2020 | $7,337,000 | -12.3% | 352,105 | 0.0% | 1.52% | -16.4% |
| Q2 2020 | $8,362,000 | +32.0% | 352,105 | 0.0% | 1.82% | +24.5% |
| Q1 2020 | $6,334,000 | -24.2% | 352,105 | 0.0% | 1.46% | -10.4% |
| Q4 2019 | $8,351,000 | +105.3% | 352,105 | +137.8% | 1.63% | +92.8% |
| Q3 2019 | $4,068,000 | -17.0% | 148,058 | 0.0% | 0.84% | -19.1% |
| Q2 2019 | $4,899,000 | -5.6% | 148,058 | 0.0% | 1.04% | +3.1% |
| Q1 2019 | $5,187,000 | +5.5% | 148,058 | 0.0% | 1.01% | -3.2% |
| Q4 2018 | $4,918,000 | -34.0% | 148,058 | 0.0% | 1.05% | -27.5% |
| Q3 2018 | $7,454,000 | -21.2% | 148,058 | -6.3% | 1.44% | -23.3% |
| Q2 2018 | $9,459,000 | +16.0% | 158,058 | -11.2% | 1.88% | +10.6% |
| Q1 2018 | $8,155,000 | +14.9% | 178,058 | 0.0% | 1.70% | +10.7% |
| Q4 2017 | $7,095,000 | -0.4% | 178,058 | 0.0% | 1.54% | -3.4% |
| Q3 2017 | $7,122,000 | +378.0% | 178,058 | +414.9% | 1.59% | +368.2% |
| Q2 2017 | $1,490,000 | -26.3% | 34,581 | -46.5% | 0.34% | -29.8% |
| Q1 2017 | $2,021,000 | -51.4% | 64,581 | -60.8% | 0.48% | -55.4% |
| Q4 2016 | $4,155,000 | +9.8% | 164,581 | 0.0% | 1.08% | +6.1% |
| Q3 2016 | $3,785,000 | -17.2% | 164,581 | -26.7% | 1.02% | -12.5% |
| Q2 2016 | $4,574,000 | +33.6% | 224,581 | 0.0% | 1.17% | +22.4% |
| Q1 2016 | $3,424,000 | +0.1% | 224,581 | -11.8% | 0.96% | +2.9% |
| Q4 2015 | $3,421,000 | -38.2% | 254,581 | -35.5% | 0.93% | -34.8% |
| Q3 2015 | $5,535,000 | -53.1% | 394,581 | -43.2% | 1.42% | -53.3% |
| Q2 2015 | $11,793,000 | +41.5% | 694,581 | 0.0% | 3.05% | +44.3% |
| Q1 2015 | $8,334,000 | +44.6% | 694,581 | 0.0% | 2.11% | +32.7% |
| Q4 2014 | $5,765,000 | +65.9% | 694,581 | +73.6% | 1.59% | +64.6% |
| Q3 2014 | $3,476,000 | +217.4% | 400,000 | +300.0% | 0.97% | +284.1% |
| Q2 2014 | $1,095,000 | – | 100,000 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |